Shionogi & Co., Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Isao Teshirogi
- Full Time Employees
- 6,223
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Park Tower Kita OS Japan 530-0011
- IPO Date
- Dec 1, 2015
- CIK
- 0001281721
- Website
- shionogi.com
- Similar Companies
- Business
- Shionogi & Co., Ltd. Shionogi & Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals, diagnostic reagents, and medical devices with a focus on infectious diseases, pain management, and high unmet medical needs. The company offers a broad portfolio of prescription drugs including anti-infectives such as cefiderocol for multidrug-resistant Gram-negative bacterial infections and baloxavir marboxil (Xofluza) for influenza; HIV therapies through royalties on dolutegravir (Dovato), cabotegravir (Apretude, Cabenuva); pain treatments like naldemedine (Symproic), duloxetine (Cymbalta), and oxycodone (Oxycontin) franchise products; cardiovascular and liver disease drugs such as lusutrombopag (Mulpleta); and other therapies for allergies (Claritin), insomnia (nitrazepam), bacterial infections (moxifloxacin), dyspareunia (Osphena), and chronic conditions. It operates through domestic prescription drugs, overseas subsidiaries and exports via entities like Shionogi Inc. in the U.S., Shionogi B.V. in Europe, and Ping An-Shionogi in China; and royalties from partners including ViiV Healthcare Ltd. for HIV franchise and other collaborators on Crestor. Shionogi & Co., Ltd. maintains global operations across Japan, North America, Europe, and Asia-Pacific, targeting patients with infectious diseases, chronic pain, metabolic disorders, immunology, and emerging areas like sleep apnea, Pompe disease, and hearing loss. Founded in 1878 and headquartered in Osaka, Japan, the company employs approximately 4,959 consolidated staff and pursues a drug-discovery-based strategy under its Shionogi Transformation Strategy 2030 Revision, emphasizing small molecule innovation and Healthcare as a Service solutions. In recent developments, Shionogi & Co., Ltd. agreed in May 2025 to acquire Japan Tobacco Inc.'s pharmaceutical business through an absorption-type split, all shares of Akros Pharma Inc. in the U.S., and full ownership of Torii Pharmaceutical Co., Ltd. via tender offer for approximately ¥160 billion ($1.1 billion) to bolster small molecule drug discovery, R&D capabilities, and pipeline advancement in cardiovascular, immunology, and central nervous system areas, with integration planned for late 2025. The company announced a corporate reorganization effective December 1, 2025, establishing the Central Pharmaceutical Research Institute and Development Business Division under its R&D unit while renaming its Venture Alliance Management Office. Shionogi & Co., Ltd. also raised its full-year operating profit guidance to ¥185 billion in October 2025, driven by strong HIV royalties, overseas growth in the U.S. (42% revenue increase) and Europe (19%), and plans to expand manufacturing in the U.S. and new drug business in China.
Company News
Shionogi to Showcase Advancements Across its Infectious Disease Portfolio at IDWeek 2026
Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Beats Q1 Earnings Estimates
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure
Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
SGIOY vs. SDZNY: Which Stock Is the Better Value Option?
Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease
SGIOY vs. SDZNY: Which Stock Should Value Investors Buy Now?
SGIOY or SDZNY: Which Is the Better Value Stock Right Now?
SGIOY vs. ZTS: Which Stock Is the Better Value Option?
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Hits New 12-Month High – Should You Buy?
Analyzing Zoetis (NYSE:ZTS) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)
Shionogi & Co., Ltd. (SGIOY) Q1 2025 Earnings Call Transcript
SGIOY or ZTS: Which Is the Better Value Stock Right Now?
SGIOY or ZTS: Which Is the Better Value Stock Right Now?
Shionogi & Co., Ltd. (SGIOY) Q3 2024 Earnings Call Transcript
Shionogi & Co. (SGIOY) Upgraded to Buy: What Does It Mean for the Stock?
Shionogi & Co., Ltd. (SGIOY) Q2 2024 Earnings Call Transcript